Search clinical trials for: Optimally Debulked

Total 28 results

Memorial Sloan Kettering Cancer Center
AstraZeneca; Genentech, Inc.

Completed

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Translational Research in Oncology

Terminated

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

Ovarian Neoplasms

United States, France, Germany, Israel, Ireland, Spain, Canada, United Kingdom
Johannes Gutenberg University Mainz

Not yet recruiting

How to Optimally Train Emotional and Social Skills

Mental Health
University of California, San Francisco
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Not yet recruiting

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Castration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IVB Prostate Cancer AJCC v8

United States
West German Study Group
Agendia

Recruiting

PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS (PROOFS)

Female Breast Cancer

Germany
North Eastern German Society of Gynaecological...
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Not yet recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Clear Cell Carcinoma
Manchester University NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust; Norfolk and Norwich University... and other collaborators

Completed

Flash-glucose Monitoring in Sub-optimally Controlled Type 1 Diabetes (FLASH-UK) (FLASH-UK)

Diabetes Mellitus, Type 1

United Kingdom
Seung-Jung Park
CardioVascular Research Foundation, Korea

Terminated

HOW To Optimally Implant BioResorbable Scaffold - Intravascular Imaging Versus Quantitative Coronary Angiography Guidance (HOWTO-BRS)

Coronary Stenosis

Korea, Republic of
Zeria Pharmaceutical

Completed

Trial to Optimally Show the Pharmacological Action of Z-100

Cervical Cancer

Vietnam
Hasselt University
Ziekenhuis Oost-Limburg

Completed

Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients (STOP-CRT)

Heart Failure (HF)

Belgium
GlaxoSmithKline

Completed

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa

Parkinson Disease

China
EPS Corporation

Completed

Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (ATOM)

Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer

Japan
EPS Corporation

Completed

Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (ATOM ES)

Colorectal Cancer | Liver Metastasis

Japan
Hoffmann-La Roche

Completed

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

Schizophrenia

United States, China, Italy, Bulgaria, Russian Federation, Japan, Czech Republic
Hoffmann-La Roche

Completed

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

Schizophrenia

Germany, Spain, Turkey, Canada, United States, Netherlands, Chile, Brazil, Taiwan, Poland, Ukraine, Slovakia, Lithuania, Latvia
Pfizer

Terminated

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Schizophrenia

United States
AstraZeneca

Completed

Real Life Effectiveness in Patients With Not Optimally Controlled Asthma

Asthma

Taiwan
University of Cambridge
Medical University of Graz; Profil Institut für Stoffwechselforschung GmbH

Completed

Closing the Loop in Adults With Sub-optimally Controlled Type 1 Diabetes Under Free Living Conditions (AP@home04)

Type 1 Diabetes

United Kingdom, Austria, Germany
Hoffmann-La Roche

Completed

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

Schizophrenia

Finland, Sweden, Korea, Republic of, United States, Colombia, France, Russian Federation, Australia, Hungary, Romania, Mexico, United Kingdom, Argentina, India
Mark Dewhirst

Withdrawn

Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca

Ovarian Cancer
Allergopharma GmbH & Co. KG

Completed

Design of Optimally-diagnostic Skin Test Solutions for Diagnosis of Sensitisation to a Pollen and Dust Mite Mixture.

Type I Allergy

Germany
Rocky Mountain Cancer Centers

Unknown

Definitive Therapy for Oligometastatic Solid Malignancies

Stage IV or Recurrent Carcinoma or Sarcoma

United States
Amgen

Completed

A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

Postmenopausal Osteoporosis
Far Eastern Memorial Hospital

Completed

Real Life Effectiveness in Patients With Not Optimally Controlled Asthma

Asthma
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.

Anxiety Disorders
Sheba Medical Center

Unknown

Comparison of Two Insulin Regimens in Optimally-controlled Patients With DM2.

Diabetes Mellitus 2 Type

Israel
National Center for Tumor Diseases, Heidelberg
Pfizer; Roche Pharma AG

Terminated

Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (APRIORI)

Colorectal Carcinoma

Germany
Sheba Medical Center

Unknown

The 3-Dimensional Ultrasound for Fetal Anomaly Scan

Pregnancy

Israel

3

Subscribe